Medically induced/surgical menopause

Key takeaways

• Medically induced menopause can be either permanent (after surgery to remove the ovaries) or temporary (during medication-based treatment), and this distinction shapes everything about how it is managed.
• Symptoms are often more severe than in natural menopause because they begin suddenly rather than gradually, and the long-term health implications for bone, heart, and brain health are significant enough to warrant proactive care.
• HRT is recommended for most women who enter medically induced menopause before the age of 45, though cancer history and individual circumstances require a carefully personalised approach with specialist input.

What makes medically induced menopause different from natural menopause

Natural menopause unfolds over years. Hormone levels decline gradually, the body adapts incrementally, and symptoms, while sometimes significant, generally emerge at a pace that allows some adjustment.

Medically induced menopause does not follow that pattern. When the ovaries are removed surgically, or their function is suppressed by medication, oestrogen levels drop sharply and immediately. There is no runway. One of the most consistent descriptions from women who have been through it is that it feels like a switch being flicked rather than a dimmer being slowly turned down.

This abruptness matters clinically as well as experientially. The sudden withdrawal of oestrogen tends to produce more intense vasomotor symptoms (hot flushes, night sweats) than the gradual decline of natural menopause. It also has more immediate implications for bone and cardiovascular health, because the body loses the protective effects of oestrogen without the years of gradual adaptation that accompany natural menopause.

Understanding this is not meant to be alarming. It is meant to explain why medically induced menopause warrants a more active management approach than "wait and see."

The causes: surgical, chemical and treatment-related

There are three main pathways to medically induced menopause, and a distinction that most content on this topic never makes clearly: whether the effect is permanent or potentially temporary.

Surgical menopause (ovary removal)

Surgical removal of both ovaries (bilateral oophorectomy) causes immediate, permanent menopause regardless of age. This may be performed as treatment for ovarian or cervical cancer, as part of risk-reduction surgery for women carrying BRCA gene variants, or as part of treatment for severe endometriosis. Menopause begins within days of surgery.

Chemical menopause (GnRH agonists)

GnRH agonists are medications that suppress ovarian function by switching off the hormonal signals from the brain that tell the ovaries to produce oestrogen. They are used to treat endometriosis, uterine fibroids, and certain hormone-sensitive cancers, and are sometimes used to protect ovarian function during chemotherapy.

The critical difference from surgery: menopause caused by GnRH agonists is potentially reversible. When the medication is stopped, ovarian function typically resumes, though this is not guaranteed and depends on age, treatment duration, and individual factors. Women taking GnRH agonists should understand from the outset whether the intended effect is temporary or long-term, and what to expect when treatment ends.

The British Menopause Society's 2026 guidance on induced menopause is explicit that add-back HRT should begin at the same time as GnRH agonist therapy, not after a delay, to prevent bone loss and manage symptoms from the start. This is frequently under-prescribed. If you are being started on a GnRH agonist and add-back therapy has not been discussed, it is worth raising.

Chemotherapy and radiotherapy

Cancer treatment can damage or destroy ovarian function, either temporarily or permanently. Whether periods and fertility return after chemotherapy depends on the type of treatment, the dose, and age at the time of treatment. Pelvic radiotherapy carries a higher risk of permanent ovarian damage. Your oncology team will be best placed to advise on what to expect in your specific situation.

Symptoms: what to expect and why they can feel more intense

The symptom profile of medically induced menopause is broadly similar to natural menopause, but the sudden onset means many women experience it more acutely.

Common symptoms include:

• Hot flushes and night sweats, often frequent and intense in the early weeks
• Sleep disruption, which compounds everything else
• Mood changes: low mood, anxiety, irritability, and emotional unpredictability
• Brain fog and difficulty concentrating
• Vaginal dryness and discomfort, which can affect both day-to-day comfort and sexual health
• Reduced libido
• Joint pain and muscle aches
• Fatigue

Sleep and mood are among the most universally reported concerns. Among Voy members receiving menopause treatment, 71% reported improved sleep and 83% reported improvement in mood and emotional symptoms (presented at The Menopause Society 2025, forthcoming in Climacteric).

One symptom worth addressing specifically: libido loss is often more pronounced in surgical menopause than in natural menopause. The reason is that the ovaries produce testosterone as well as oestrogen and progesterone. Surgical removal of both ovaries eliminates this source of testosterone entirely, causing an abrupt drop that has a direct effect on sexual desire, arousal, and energy. This is covered further in the section on testosterone below.

The long-term health picture: bone, heart and brain

This section covers information that every woman facing medically induced menopause deserves to know, not to create anxiety, but because early awareness enables proactive management that makes a real difference.

Bone health

Oestrogen plays a central role in maintaining bone density. Sudden loss of oestrogen accelerates bone thinning significantly. A systematic review published in BJOG confirmed substantially higher rates of osteoporosis and fracture following surgical menopause compared with natural menopause. Women under 45 who undergo surgical menopause are at particularly high risk. A baseline DEXA (bone density) scan and regular monitoring are recommended, and HRT, where appropriate, reduces this risk significantly.

Heart health

A large UK Biobank cohort study published in JAMA (2019), involving over 144,000 women, found that both premature natural and surgical menopause were associated with a significant increase in cardiovascular disease risk (heart disease and stroke). A 2023 systematic review and meta-analysis across over 921,000 women confirmed that premature menopause is associated with elevated risk of cardiovascular disease, type 2 diabetes, and metabolic syndrome. These are not reasons to panic: they are reasons to ensure cardiovascular health is monitored and that any modifiable risk factors (blood pressure, cholesterol, weight, smoking) are addressed proactively.

Cognitive health

Research in this area is more limited and should be interpreted carefully. A 2019 systematic review in Psychoneuroendocrinology found that surgical menopause before the age of 45 was associated with a higher risk of dementia and faster decline in verbal memory and processing speed. The authors themselves flag the evidence as limited and the findings as requiring further investigation. This is an area of active research rather than a settled conclusion, and the evidence does not apply to women who enter surgical menopause closer to the natural age.

What the evidence does support is that proactive hormonal management (where appropriate) is thought to be protective across all three of these domains. The goal of this information is to motivate good care, not to add to the weight of what you are already carrying.

HRT after medically induced menopause: who it helps and what the evidence says

HRT is a central part of managing medically induced menopause for most women, but the picture varies significantly depending on individual circumstances.

Women under 45 with no contraindications:

The British Menopause Society's Surgical Menopause Toolkit (2024) is clear: HRT plays a significant role in managing surgical menopause, particularly in women under 45. This reflects the evidence that HRT reduces bone loss, likely lowers long-term cardiovascular risk, and improves quality of life. A 2025 review in PMC confirmed that HRT initiated after surgical menopause before age 45 is linked to improvements in cardiovascular outcomes, fracture risk, cognitive function, and overall wellbeing, and that international guidelines recommend initiating it (barring contraindications) and continuing at least until the age of natural menopause, around 52.

“It is no understatement to say that HRT is life-prolonging for women who go through menopause under age 45.”

Katy Jackson, Clinical Director - Women's Health

GnRH agonist treatment: add-back from the start:

As noted above, BMS guidance (2026) is explicit: add-back HRT should begin at the same time as GnRH agonist therapy, not after a period of unmanaged menopause symptoms. This recommendation is specifically to prevent bone loss as well as to manage vasomotor and mood symptoms. If this was not offered when your treatment began, it is worth discussing with your prescribing team.

BRCA carriers after risk-reducing ovary removal:

Women who carry BRCA1 or BRCA2 gene variants and undergo risk-reducing ovary removal (oophorectomy) are often, understandably, anxious about HRT. Current guidance from the British Menopause Society (2024) indicates that HRT can be used after risk-reducing surgery and does not appear to diminish the cancer risk-reduction benefit of the surgery itself. The clinical data in this specific population remains limited, however, and the decision should be made in discussion with both your menopause specialist and your oncology team, taking your full personal history into account.

Women with a history of hormone-sensitive cancer:

This is where individual assessment is most critical. For women with a history of breast cancer or other hormone-sensitive cancers, non-hormonal approaches are generally considered first. If those approaches do not adequately manage symptoms, HRT may be discussed, but this must involve the oncology team and careful shared decision-making. There is no blanket answer. If you have a history of cancer, your specialist will discuss all your options, including treatments that may still be suitable for your circumstances.

Non-hormonal options when HRT is not suitable

For women who cannot take systemic HRT, or who prefer to explore alternatives first, there are several evidence-supported options.

Vasomotor symptoms:

SSRIs and SNRIs (antidepressants) have good evidence for reducing hot flush frequency and severity. Gabapentin is another option. Neither is a hormone, and both can be used in most women with hormone-sensitive cancer histories.

Vaginal health:

Vaginal oestrogen (topical, locally applied oestrogen) has minimal systemic absorption and is generally considered appropriate even for many women who cannot take systemic HRT. It is highly effective for vaginal dryness, discomfort, and urinary symptoms. Topical DHEA (prasterone) and vaginal moisturisers are further options. Confirm appropriateness with your specialist if you have a hormone-sensitive cancer history.

Mood and psychological symptoms:

Cognitive Behavioural Therapy (CBT) has good evidence for managing menopause-related anxiety, low mood, and sleep disruption. Voy offers structured CBT as part of its menopause service, which can be particularly relevant for women who are navigating both a health diagnosis and sudden menopause.

Testosterone: the hormone that often goes unmentioned

The ovaries produce testosterone as well as oestrogen. This is not widely known, and its clinical implications for surgical menopause are significant.

When both ovaries are removed, testosterone levels drop abruptly alongside oestrogen. This is distinct from natural menopause, where testosterone declines more gradually. The result is that libido loss, reduced sexual arousal, low energy, and motivation difficulties are often more pronounced after surgical menopause than after natural menopause.

Testosterone treatment is an evidence-based option for addressing these symptoms. Voy's menopause service includes testosterone treatment plans (available as Testogel, Androfeme, or Voy's Testosterone cream), and a testosterone blood test within the last three months is required before a prescription can be issued. The BMS Surgical Menopause Toolkit (2024) supports testosterone as part of comprehensive care for women following surgical menopause.

If libido and energy have been significantly affected and have not improved with oestrogen-based HRT alone, testosterone assessment is worth raising with your specialist.

Fertility and timing: what to ask before treatment begins

For women of reproductive age who are approaching surgery or treatment that will induce menopause, the fertility question deserves to be raised before treatment starts, not after.

Egg or embryo freezing before oophorectomy or chemotherapy can preserve options for the future. Whether this is possible and appropriate depends on the urgency of treatment, the diagnosis, and individual circumstances. If you are facing planned surgery or treatment and fertility matters to you, ask your surgical or oncology team about referral to a fertility specialist before proceeding.

For GnRH agonist-induced menopause, the position is different. Because the effect is potentially reversible, fertility may return when the medication is stopped. Discuss with your prescribing team what to expect in your specific situation.

The emotional side: what many women are not told

Coping with medically induced menopause alongside a health diagnosis or recovery from surgery is genuinely one of the harder things a person can go through. The physical symptoms of sudden menopause are one layer. The emotional experience of arriving at menopause unexpectedly, often before it was expected and sometimes accompanied by grief at the loss of fertility or a sense of bodily control, is another.

Many women describe feeling caught between two things: their medical team is focused on treatment and recovery, and the menopause piece can feel like an afterthought. The flushing, the sleeplessness, the mood changes, the loss of libido: these are real and they matter, even in the context of a bigger health picture.

83% of Voy members receiving menopause treatment reported improvement in mood and emotional symptoms (presented at The Menopause Society 2025, forthcoming in Climacteric). That data comes from women across many different circumstances. Getting the right hormonal support does make a difference, including to the emotional weight of the experience.

If you are struggling with the psychological dimensions of this, CBT has good evidence for menopause-related anxiety and low mood, and Voy offers structured CBT as part of its menopause service. The peer support programme, including 1:1 peer mentoring (rated 4.9/5 by participants), offers the specific comfort of connecting with women who have been through something similar.

You do not have to manage this in the margins of your other treatment.

Getting the right support

Medically induced menopause warrants specialist care. A GP appointment, particularly a short one, is rarely the right setting for the conversation this situation needs: one that covers HRT suitability in your specific clinical context, testosterone assessment, bone monitoring, cardiovascular health, and the emotional picture.

88% of Voy members felt more hormonally balanced at three months, compared to 62% receiving standard care (presented at The Menopause Society 2025, forthcoming in Climacteric). That gap reflects what a properly resourced, personalised approach to menopause care produces.

Voy's menopause consultations are 45 minutes with BMS-trained (British Menopause Society) specialists. That time allows for a proper history, a considered assessment of what is and is not appropriate for your circumstances, and a treatment plan that reflects the full picture rather than the first available option.